Literature DB >> 20664474

The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum.

Lowell B Anthony1, Jonathan R Strosberg, David S Klimstra, William J Maples, Thomas M O'Dorisio, Richard R P Warner, Gregory A Wiseman, Al B Benson, Rodney F Pommier.   

Abstract

Neuroendocrine tumors (NETs) of the distal colon and rectum are also known as hindgut carcinoids based on their common embryologic derivation. Their annual incidence in the United States is rising, primarily as a result of increased incidental detection. Symptoms of rectal NETs include hematochezia, pain, and change in bowel habits. Most rectal NETs are small, submucosal in location, and associated with a very low malignant potential. Tumors larger than 2 cm or those invading the muscularis propria are associated with a significantly higher risk of metastatic spread. Colonic NETs proximal to the rectum are rarer and tend to behave more aggressively. The incidence of rectal NETs in African Americans and Asians is substantially higher than in Caucasians. Colorectal NETs are generally not associated with a hormonal syndrome such as flushing or diarrhea. A multidisciplinary approach is recommended in diagnosing and managing hindgut NETs.

Entities:  

Mesh:

Year:  2010        PMID: 20664474     DOI: 10.1097/MPA.0b013e3181ec1261

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  83 in total

Review 1.  Which endoscopic treatment is the best for small rectal carcinoid tumors?

Authors:  Hyun Ho Choi; Jin Su Kim; Dae Young Cheung; Young-Seok Cho
Journal:  World J Gastrointest Endosc       Date:  2013-10-16

2.  Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.

Authors:  David A Kleiman; Toni Beninato; Samuel Sultan; Michael J P Crowley; Brendan Finnerty; Ritu Kumar; Nicole C Panarelli; Yi-Fang Liu; Michael D Lieberman; Marco Seandel; Todd Evans; Olivier Elemento; Rasa Zarnegar; Thomas J Fahey
Journal:  Ann Surg Oncol       Date:  2014-05-23       Impact factor: 5.344

Review 3.  Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila.

Authors:  Vaibhav Rastogi; Devina Singh; Joseph J Mazza; Dipendra Parajuli; Steven H Yale
Journal:  Clin Med Res       Date:  2018-04-12

Review 4.  Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.

Authors:  Ashok R Gunawardene; Bernard M Corfe; Carolyn A Staton
Journal:  Int J Exp Pathol       Date:  2011-04-25       Impact factor: 1.925

5.  Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion.

Authors:  Masau Sekiguchi; Shigeki Sekine; Taku Sakamoto; Yosuke Otake; Takeshi Nakajima; Takahisa Matsuda; Hirokazu Taniguchi; Ryoji Kushima; Yuichiro Ohe; Yutaka Saito
Journal:  J Gastroenterol       Date:  2015-05-05       Impact factor: 7.527

Review 6.  Antitumor effects of somatostatin analogs in neuroendocrine tumors.

Authors:  Lucas Sidéris; Pierre Dubé; Anja Rinke
Journal:  Oncologist       Date:  2012-05-24

Review 7.  Early Gastroenteropancreatic Neuroendocrine Tumors: Endoscopic Therapy and Surveillance.

Authors:  Hans Scherübl; Guillaume Cadiot
Journal:  Visc Med       Date:  2017-10-10

8.  Surveillance strategy for rectal neuroendocrine tumors according to recurrence risk stratification.

Authors:  Dong Hyun Kim; Jin Ha Lee; Yoon Jin Cha; Soo Jung Park; Jae Hee Cheon; Tae Il Kim; Hoguen Kim; Won Ho Kim; Sung Pil Hong
Journal:  Dig Dis Sci       Date:  2013-12-10       Impact factor: 3.199

Review 9.  Rectal carcinoids: a systematic review.

Authors:  Frank D McDermott; Anna Heeney; Danielle Courtney; Helen Mohan; Des Winter
Journal:  Surg Endosc       Date:  2014-03-01       Impact factor: 4.584

Review 10.  Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned.

Authors:  James C Yao; Diane Reidy Lagunes; Matthew H Kulke
Journal:  Oncologist       Date:  2013-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.